Revisiting the framework of the National Institute on Aging-Alzheimer's Association diagnostic criteria

In 2011, the National Institute on Aging and the Alzheimer's Association (NIA‐AA) proposed revising the criteria for diagnosing Alzheimer's disease (AD), which had been established more than 25 years earlier by the National Institute on Neurologic and Communicative Disorders and Stroke (NINCDS) and the Alzheimer's Disease and Related Disorders Association (ADRDA), now called the Alzheimer's Association. The NIA‐AA initiative also built upon research criteria for AD proposed by the International Working Group (IWG) in 2007 and updated in 2010. These efforts to revise the criteria reflect the need to improve diagnostic accuracy, facilitate clinical trials, and establish a common set of criteria that are universally accepted across domains of clinical practice, research, and drug development. To ensure that the proposed NIA‐AA criteria remain as current as possible, the Alzheimer's Association Research Roundtable convened a meeting in Washington, DC, on October 1 and 2, 2012, bringing together international stakeholders from industry, academia, and regulatory agencies to identify areas of agreement and research gaps respective of NIA‐AA criteria and IWG recommendations.

[1]  W. M. van der Flier,et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.

[2]  W. M. van der Flier,et al.  Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[3]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[4]  Sandra Weintraub,et al.  Reducing case ascertainment costs in U.S. population studies of Alzheimer’s disease, dementia, and cognitive impairment—Part 2 , 2011, Alzheimer's & Dementia.

[5]  Lippincott Williams Wilkins,et al.  THERMOREGULATION: RECENT CONCEPTS AND REMAINING QUESTIONS , 2008, Neurology.

[6]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[7]  P. Visser,et al.  Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. , 2010, Journal of Alzheimer's disease : JAD.

[8]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[9]  Nick C Fox,et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.

[10]  M. Mintun,et al.  Amyloid deposition, hypometabolism, and longitudinal cognitive decline , 2012, Annals of neurology.

[11]  Cindee M. Madison,et al.  Comparing predictors of conversion and decline in mild cognitive impairment , 2010, Neurology.

[12]  R. Petersen,et al.  Can we prevent Alzheimer's disease? Secondary “prevention” trials in Alzheimer's disease , 2013, Alzheimer's & Dementia.

[13]  W. M. van der Flier,et al.  Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic , 2010, Dementia and Geriatric Cognitive Disorders.

[14]  F. Lopera,et al.  Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study , 2011, The Lancet Neurology.

[15]  S. Leurgans,et al.  The neuropathology of probable Alzheimer disease and mild cognitive impairment , 2009, Annals of neurology.

[16]  F. Jessen,et al.  Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease , 2012, Neurology.

[17]  Nick C Fox,et al.  Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.

[18]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[19]  A. Burns.  Clinical diagnosis of Alzheimer's disease , 1991 .

[20]  M. Albert,et al.  Introduction to Revised Criteria for the Diagnosis of Alzheimer ’ s Disease : National Institute on Aging and the Alzheimer Association Workgroups , 2011 .

[21]  M. Albert,et al.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[22]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[23]  Nick C Fox,et al.  The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease , 2011 .

[24]  Philip Scheltens,et al.  Comparison of International Working Group criteria and National Institute on Aging–Alzheimer’s Association criteria for Alzheimer’s disease , 2012, Alzheimer's & Dementia.

[25]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup , 2011 .

[26]  Keith A. Johnson,et al.  Cognition, Reserve, and Amyloid Deposition in Normal Aging , 2009, Annals of neurology.

[27]  Vijaya L. Melnick,et al.  Alzheimer’s Dementia , 1985, Contemporary Issues in Biomedicine, Ethics, and Society.

[28]  Z. Khachaturian.  Revised criteria for diagnosis of Alzheimer’s disease: National Institute on Aging-Alzheimer's Association diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[29]  J. Trojanowski,et al.  Cognitive and functional resilience despite molecular evidence of Alzheimer’s disease pathology , 2013, Alzheimer's & Dementia.

[30]  W. M. van der Flier,et al.  Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort , 2012, Neurology.

[31]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup , 2011 .

[32]  Reisa A. Sperling,et al.  Face-name associative memory performance is related to amyloid burden in normal elderly , 2011, Neuropsychologia.

[33]  B. Dubois,et al.  Validity of the Free and Cued Selective Reminding Test in predicting dementia , 2010, Neurology.

[34]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.